Short answer
ALUMIS INC. (ALMS) filed an 8-K current report with the SEC on August 13, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 fiscal 2026 results for quarter ended June 30, 2026.
ALUMIS INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 fiscal 2026 results for quarter ended June 30, 2026
- Press release issued August 13, 2026
- Detailed financial figures and management commentary in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- ONWARD3 showed 54% PASI 100 and 75% PASI 90 at 48 weeks, strengthening envudeucitinib’s psoriasis commercial positioning
- FDA NDA submission for moderate-to-severe plaque psoriasis remains targeted for Q4 2026, a key regulatory catalyst
- LUMUS Phase 2b SLE topline data expected in Q3 2026, potentially validating expansion into interferon-driven diseases
- Cash, cash equivalents and marketable securities totaled $502.3M, funding operations and capital needs into Q4 2027
- Net loss reached $142.2M, including a $41.8M lonigutamab impairment after pursuing strategic alternatives for the program
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ALUMIS INC. 8-K filings
Get the next ALMS 8-K as it lands
Follow ALMS for push alerts, or ask the research agent what this filing means.